Antibodies to Dopamine as Neuromodulators of Behavioral Responses of Mice of Different Genotypes

Science Research Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow.
Neuroscience and Behavioral Physiology 07/2003; 33(5):507-12. DOI: 10.1023/A:1023471402939
Source: PubMed


The possibility of long-term changes in the innate characteristics of the behavior of mice of different genotypes (C57Bl/6 and BALB/c) after active immunization with dopamine-BSA conjugates was studied. These experiments revealed significant differences in the effects of anti-dopamine antibody on behavioral responses in an open field and neurotransmitter contents of brain structures in mice of different lines. Immunization with the dopamine-protein conjugate led to increases in the functional activity of the corresponding brain receptors, to different extents in mice of different lines.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A study was made of the effects of serotonin uptake inhibition and receptor blockade on the increase in rat striatal homovanillic acid and 3,4-dihydroxyphenylacetic acid and on some behavioural responses induced by haloperidol. The serotonin uptake inhibitors CGP 6085 A (4-(5,6-dimethyl-2-benzofuranyl)-piperidine-HCl), citalopram (Lu 10-171), fluoxetine (Lilly 110140), and clomipramine potentiated the increase in striatal deaminated dopamine metabolites after the neuroleptic. In contrast, the serotonin antagonists methysergide, mianserin and cinanserin antagonized the acceleration of dopamine turnover induced by haloperidol. The catalepsy induced by this neuroleptic was potentiated by CGP 6085 A and citalopram. These 5-HT uptake inhibitors also potentiated the antagonism by haloperidol of apomorphine-induced stereotypies. These results seem to make it worthwhile to test a combination of haloperidol and a serotonin antagonist in schizophrenic patients to see whether the ratio of the therapeutic effect to the extrapyramidal side effects can be improved.
    European Journal of Pharmacology 06/1979; 55(4):363-73. DOI:10.1016/0014-2999(79)90110-9 · 2.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Active immunization with dopamine conjugated with bovine serum albumin (DA-BSA) or BSA with complete Freund's adjuvant (CFA) partly suppressed the development of the MPTP-induced depressive syndrome in rats preventing the appearance of "behavioral despair" symptoms: increase in immobility time and higher index of depression in forced-swim test. In DA-BSA-immunized rats the content of DOPA, DA, HVA, NA, and 5-HN in caudate putamen and that of NA in the frontal cortex was increased, while in BSA-immunized rats the content of 5-HT in both brain areas and that of DOPAC in the frontal cortex was decreased both in rats with reduced depressive syndrome and in saline control as compared with intact animals a day after the last drug injection. In DA-BSA-immunized rats with reduced depressive syndrome the increase in DA and 5-HT content in caudate putamen was less expressed and DOPAC content was lower than in saline control. In BSA-immunized depressive rats DA content in the frontal cortex was also reduced as compared to control.
    Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova 03/2000; 50(2):287-302. · 0.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The antibodies to serotonin modulate behavioural reactions of animals depending on the mode of administration (intracerebroventricular or intraperitoneal) and the testing time. Intraventricular injection induces inhibition of behavioural activity within 1--2 hours. Systemic injection produces a biphasic effect on the serotoninergic system, i. e., the activation in the early period and the steady inhibition later. Effects of the intraperitoneally injected serotonin antibodies on the CNS are probably mediated either by serotonin binding in blood or by involvement of neurotrophic factors of the immune system. Both ways of administration of the serotonin antibodies result in late hyperalgesia.
    Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova 46(1):129-36. · 0.11 Impact Factor
Show more